{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:15:39Z","timestamp":1763442939729,"version":"3.45.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary splenic angiosarcoma (PSA) is an exceedingly rare and aggressive malignancy with a poor prognosis. This report aims to present a rare case of PSA that progressed to fatal hepatic rupture due to rapid metastatic spread following splenectomy and adjuvant therapy; a review of the relevant literature is also provided to discuss the diagnostic and therapeutic challenges associated with this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 52-year-old male patient presented with acute abdominal pain and hypovolemic shock. Imaging revealed splenic rupture with hemoperitoneum. An emergency splenectomy was performed, and histopathological examination confirmed the diagnosis of angiosarcoma. The patient received postoperative chemotherapy (liposomal paclitaxel) and subsequent targeted therapy (sunitinib). However, rapid hepatic metastasis occurred, leading to spontaneous hepatic rupture and death 6 months after the initial diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The condition poses a diagnostic and therapeutic challenge due to its nonspecific presentation and high aggressiveness. Early splenectomy remains the prevailing standard of care. This case demonstrates the potential inefficacy of sunitinib against PSA-derived hepatic metastases and emphasizes the critical importance of early diagnosis and intervention before splenic rupture occurs. The potential for combination therapies, including immunotherapy, to represent future investigative avenues is a promising area for future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1708613","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:13:25Z","timestamp":1763442805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Spontaneous hepatic rupture: A catastrophic complication in a patient with primary splenic angiosarcoma and hepatic metastasis: case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhidan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000493656","article-title":"Clinical characteristics and prognostic factors of primary splenic angiosarcoma: A retrospective clinical analysis from China","volume":"49","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016245","article-title":"A primary splenic angiosarcoma hepatic metastasis after splenectomy and its genomic alteration profile","volume":"98","author":"Cao","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199310000-00001","article-title":"Primary angiosarcoma of the spleen. A clinicopathologic study of 40 cases","volume":"17","author":"Falk","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4905726","DOI":"10.1155\/2016\/4905726","article-title":"Primary angiosarcoma of the spleen: rare diagnosis with atypical clinical course","volume":"2016","author":"Kohutek","year":"2016","journal-title":"Case Rep Oncol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1945920","article-title":"Spleen angiosarcoma: a world review","volume":"15","author":"Juin Hsien","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-22-22","article-title":"Images in immunotherapy and precision oncology: angiosarcoma of the spleen and liver","volume":"6","author":"Deshpande","year":"2023","journal-title":"J Immunother Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4322\/acr.2019.100","article-title":"Primary splenic angiosarcoma: a rare entity often associated with rupture and hemoperitoneum","volume":"9","author":"Fiorentino","year":"2019","journal-title":"Autops Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009718","article-title":"Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen: A care-compliant case report and literature review","volume":"97","author":"Chen","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1477-7819-11-53","article-title":"Spontaneous rupture of primary splenic angiosarcoma: a case report and literature review","volume":"11","author":"Duan","year":"2013","journal-title":"World J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S5329","article-title":"Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review","volume":"4","author":"Vakkalanka","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000452619","article-title":"Splenic angiosarcoma: A diagnostic splenectomy finding","volume":"9","author":"de Azevedo","year":"2016","journal-title":"Case Rep Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","article-title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","volume":"6","author":"Paoluzzi","year":"2016","journal-title":"Clin Sarcoma Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i9.2818","article-title":"Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review","volume":"10","author":"Pan","year":"2022","journal-title":"World J Clin Cases"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc\u00a0Natl Acad Sci U.S.A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jvir.2024.09.014","article-title":"Radioembolization of primary splenic angiosarcoma complicated by delayed gastric hemorrhage","volume":"36","author":"Garg","year":"2025","journal-title":"J Vasc Interventional Radiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1366560","article-title":"Application value of (18)F-FDG PET\/CT in primary spleen angiosarcoma with liver metastasis: a case report and literature review","volume":"14","author":"Shao","year":"2024","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809068","article-title":"Case report: complete remission with anti-PD-1 and anti-VEGF combined therapy of a patient with metastatic primary splenic angiosarcoma","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000519211","article-title":"Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma","volume":"15","author":"Takehara","year":"2021","journal-title":"Case Rep Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5152\/turkjsurg.2017.3207","article-title":"Primary splenic angiosarcoma diagnosed after splenectomy for spontaneous rupture","volume":"34","author":"Ozcan","year":"2018","journal-title":"Turk J Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1179\/1973947813Y.0000000146","article-title":"Rapidly progressing primary splenic angiosarcoma with fatal hemorrhagic event","volume":"26","author":"Cho","year":"2014","journal-title":"J\u00a0Chemother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2012.e55","article-title":"Systemic therapy in primary angiosarcoma of the spleen","volume":"4","author":"Ferreira","year":"2012","journal-title":"Rare Tumors"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4293\/108680810X12924466006521","article-title":"Primary splenic angiosarcoma","volume":"14","author":"Hamid","year":"2010","journal-title":"JSLS"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1708613\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:13:26Z","timestamp":1763442806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1708613\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1708613"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1708613","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"1708613"}}